Natco Pharma Ltd - 524816 - Statement Of Investor Complaints For The Quarter Ended June 2019
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0660 Name of the Signatory :- M AdinarayanaDesignation :- Company Secretary and Compliance Officer NATCO PHARMA LTD. - 524816 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Venkata Satya Swathi Kantamani & PACs NATCO PHARMA LTD. - 524816 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for V C Nannapaneni & PACs Natco Pharma Ltd - 524816 - Related Party Transactions For The Year Ended March 31, 2019
Related Party Transactions for the year ended March 31, 2019 Natco Pharma Ltd - 524816 - Disclosures under Reg. 10(5) in respect of acquisition under Reg. 10(1)(a) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 10(5) in respect of acquisition under Regulation 10(1)(a) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Venkata Satya Swathi Kantamani NATCO PHARMA LTD. - 524816 - Disclosures under Reg. 10(5) in respect of acquisition under Reg. 10(1)(a) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 10(5) in respect of acquisition under Regulation 10(1)(a) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Venkata Satya Swathi Kantamani NATCO PHARMA LTD. - 524816 - Disclosure Under Regulation 30.Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Disclosure under Regulation 30.of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Natco Pharma: Good prognosis
Pipeline of niche launches in the US and shift in focus to other geographies should pay off Natco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor presentation for the quarter and year ended March,19